Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

By Jizhong Liu, A. Hamrouni, D. Wołowiec, V. Coiteux, K. Kuliczkowski, D. Hétuin, A. Saudemont, B. Quesnel. Blood, 2007

610 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. (2016, background): “Any grade AE in $ 5% of patients and all grade $ 3 AEs Nonhematologic Fatigue 14 (17) 0 Pneumonitis 9 (11) 3 (4) Decreased appetite 7 (9) 0 Pruritus 7 (9) 0 Rash 7 (9) 1 (1) Diarrhea 6 (7) 0 Pyrexia 6 (7) 0 Hypocalcemia 5 (6) 0 Blood creatine phosphokinase increased 3 (4) 1 (1)”
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways (2008, background): “Treatment with anti-PD-L1 in vivo delayed tumorigenesis but did not halt myeloma tumor cell growth (154).”
PD-1 and its ligands in tolerance and immunity. (2008, background): “PD-L1 expression in cell lines is decreased when MyD88, TRAF6, and MEK are inhibited (28).”